Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

A phase I, open‐label study (NCT02197234) assessed the effects of osimertinib on simvastatin exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer and disease progression post‐EGFR tyrosine kinase inhibitor treatment. Here, we report on a retro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Transl Sci
Päätekijät: Vishwanathan, Karthick, Cantarini, Mireille, So, Karen, Masson, Eric, Fetterolf, Jennifer, Ramalingam, Suresh S., Harvey, R. Donald
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6951454/
https://ncbi.nlm.nih.gov/pubmed/31498564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12688
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia